INTERFERONALFA-2B-JordanUniversityofScienceand：干扰素α-2b-乔丹科技大学.pdfVIP

INTERFERON ALFA-2B CLASS: Interferon INDICATIONS: Patients ≥1 year of age: Chronic hepatitis B Patients ≥3 years of age: Chronic hepatitis C (in combination with ribavirin) Patients ≥18 years of age: Condyloma acuminata, chronic hepatitis B, chronic hepatitis C, hairy cell leukemia, malignant melanoma (high-risk of recurrence), AIDS- related Kaposis sarcoma, follicular non-Hodgkin lymphoma AVAILABLE DOSAGE FROM THE HOSPITAL: TRADE NAMES: DOSAGE:  Dosing: Adult Details concerning dosing in combination regimens should also be consulted. Consider premedication with acetaminophen prior to administration to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details. Hairy cell leukemia: I.M., SubQ: 2 million units/m2 3 times weekly for up to 6 months (may continue treatment with sustained treatment response); discontinue for disease progression or failure to respond after 6 months Lymphoma (follicular): SubQ: 5 million units 3 times weekly for up to 18 months Malignant melanoma: Induction: 20 million units/m2 I.V. for 5 consecutive days per week for 4 weeks, followed by maintenance dosing of 10 million units/m2 SubQ 3 times weekly for 48 weeks AIDS-related Kaposis sarcoma: I.M., SubQ: 30 million units/m2 3 times weekly; continue until disease progression or until maximal response has been achieved after 16 weeks Chronic hepatitis B: I.M., SubQ: 5 million units/ daily or 10 million units 3 times weekly for 16 weeks Chronic hepatitis C: I.M., SubQ: 3 million units 3 times weekly. In patients with normalization of ALT at 16 weeks, continue treatment (if tolerated) for 18-24 months; consider discontinuation if normalization does not occur at 16 weeks. Note: May be used in combination therapy with ribavirin in previously untreated patients or in patients who